JP2013510885A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510885A5
JP2013510885A5 JP2012539065A JP2012539065A JP2013510885A5 JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5 JP 2012539065 A JP2012539065 A JP 2012539065A JP 2012539065 A JP2012539065 A JP 2012539065A JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5
Authority
JP
Japan
Prior art keywords
formula
composition
compound
nhch
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539065A
Other languages
English (en)
Japanese (ja)
Other versions
JP5650233B2 (ja
JP2013510885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056760 external-priority patent/WO2011060392A1/en
Publication of JP2013510885A publication Critical patent/JP2013510885A/ja
Publication of JP2013510885A5 publication Critical patent/JP2013510885A5/ja
Application granted granted Critical
Publication of JP5650233B2 publication Critical patent/JP5650233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539065A 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 Active JP5650233B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US61/261,301 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013235966A Division JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Division JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Publications (3)

Publication Number Publication Date
JP2013510885A JP2013510885A (ja) 2013-03-28
JP2013510885A5 true JP2013510885A5 (enExample) 2014-01-09
JP5650233B2 JP5650233B2 (ja) 2015-01-07

Family

ID=43992106

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012539065A Active JP5650233B2 (ja) 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP2498610B2 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101752124B1 (enExample)
CN (2) CN105061350B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR122018077504B8 (enExample)
CA (2) CA2780772C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK2498610T4 (enExample)
EA (2) EA024801B1 (enExample)
ES (2) ES2858337T3 (enExample)
FI (1) FI2498610T4 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE037535T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT3406142T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY161854A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL2498610T5 (enExample)
PT (2) PT2498610T (enExample)
RS (2) RS61829B1 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI2498610T2 (enExample)
SM (2) SMT201800288T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780433C (en) * 2009-11-13 2018-01-02 Receptos, Inc. Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
RS61829B1 (sr) 2009-11-13 2021-06-30 Receptos Llc Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
RS56073B1 (sr) * 2012-06-21 2017-10-31 Eisai R&D Man Co Ltd Novi derivati indansulfamida
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
WO2016164180A1 (en) 2015-04-06 2016-10-13 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
EP4566676A3 (en) 2016-06-14 2025-11-05 Receptos LLC Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
ES2877686T3 (es) 2016-07-22 2021-11-17 Shijiazhuang Sagacity New Drug Dev Co Ltd Agonista S1P1 y aplicación del mismo
CN109563059A (zh) 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
US10882830B2 (en) 2016-09-14 2021-01-05 Receptos Llc Crystal form of ozanimod hydrochloride and processes for preparation therefor
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
EP3590929B1 (en) * 2017-02-28 2021-09-15 Medshine Discovery Inc. Spiro compound and use thereof
CN110612292A (zh) * 2017-04-07 2019-12-24 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
US11207301B2 (en) 2017-05-08 2021-12-28 Receptos Llc Sphingosine 1 phosphate receptor agonists for neuroprotection
WO2018215807A1 (en) * 2017-05-22 2018-11-29 Egis Gyógyszergyár Zrt. Process for the production of ozanimod
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
US11117876B2 (en) 2017-08-31 2021-09-14 Receptos Llc Crystalline form of ozanimod hydrochloride, and processes for preparation thereof
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
JP2021511375A (ja) 2018-01-18 2021-05-06 シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド 三環式化合物の結晶形、塩形及びその製造方法
WO2019181854A1 (ja) 2018-03-20 2019-09-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 てんかん治療剤
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
CA3124986A1 (en) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
AU2019338657A1 (en) 2018-09-12 2021-03-18 Pharmazell Gmbh A process for the preparation of Ozanimod and its intermediate (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020115200A1 (en) * 2018-12-07 2020-06-11 Synthon B.V. Improved process for preparing ozanimod
JP2022528467A (ja) * 2019-03-29 2022-06-10 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
KR20210151068A (ko) * 2019-03-29 2021-12-13 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
JP2022527999A (ja) * 2019-03-29 2022-06-07 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
EP3959204A4 (en) * 2019-04-26 2022-12-28 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
MX2022000651A (es) 2019-07-16 2022-03-11 Synthon Bv Proceso mejorado para preparar ozanimod.
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
BR112022012846A2 (pt) * 2020-01-06 2022-09-06 Arena Pharm Inc Métodos de tratamento de condições relacionadas ao receptor s1p1
US11760751B2 (en) 2020-03-04 2023-09-19 Helioeast Science & Technology Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
JP7443550B2 (ja) * 2020-03-04 2024-03-05 ヒーリオイースト ファーマシューティカル カンパニー リミテッド 三環系化合物及びその使用
WO2021188326A1 (en) * 2020-03-17 2021-09-23 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
KR20220160009A (ko) 2020-03-27 2022-12-05 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
EP4126828A1 (en) * 2020-03-27 2023-02-08 Receptos Llc Sphingosine 1 phosphate receptor modulators
EP4126826A1 (en) 2020-04-02 2023-02-08 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
CN116867771B (zh) * 2021-04-09 2025-08-26 南昌弘益药业有限公司 噁二唑取代的螺环类化合物及其应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
EP0583346A1 (en) 1991-04-12 1994-02-23 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
ID25477A (id) * 1998-01-23 2000-10-05 Sankyo Co Turunan-turunan spiropiperidin
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
JP4516430B2 (ja) 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
DK1618098T3 (en) 2003-04-11 2015-01-12 Ptc Therapeutics Inc 1,2,4-OXADIAZOLBENZOESYREFORBINDELSER AND THEIR USE FOR nonsense CONTROL AND TREATMENT OF AN ILLNESS
JP2007528872A (ja) * 2003-10-01 2007-10-18 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
JP2008531546A (ja) 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
JP5665271B2 (ja) † 2005-08-03 2015-02-04 ノバルティス アーゲー 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
US7902336B2 (en) 2005-12-21 2011-03-08 Joseph Gabriele Catecholamine regulated protein
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2008035239A1 (en) * 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
AU2007323540A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
SG177221A1 (en) 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106226A2 (en) 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
ES2549761T3 (es) 2008-05-14 2015-11-02 The Scripps Research Institute Nuevos moduladores de los receptores de esfingosina fosfato
CN102066752B (zh) * 2008-06-13 2014-02-19 (学)斗源学院 具有回转阀的往复式压缩机
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
RS61829B1 (sr) 2009-11-13 2021-06-30 Receptos Llc Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
EP2498609B1 (en) 2009-11-13 2018-04-18 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
CA2780433C (en) 2009-11-13 2018-01-02 Receptos, Inc. Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD

Similar Documents

Publication Publication Date Title
JP2013510885A5 (enExample)
JP2015505296A5 (enExample)
JP2014506907A5 (enExample)
JP2016534063A5 (enExample)
JP2011527691A5 (enExample)
JP2013032389A5 (enExample)
JP2013537203A5 (enExample)
JP2012092103A5 (enExample)
SI2498610T1 (en) SELECTIVE MODERATORS OF SFINGOSIN-1-PHOSPHATE RECEPTOR AND CIRAL SYNTHESIS PROCEDURES
JP2009242409A5 (enExample)
JP2012532883A5 (enExample)
JP2009535358A5 (enExample)
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
JP2020507589A5 (enExample)
JP2009504748A5 (enExample)
JP2009542613A5 (enExample)
JP2010536766A5 (enExample)
JP2018537535A5 (enExample)
JP2007302689A5 (enExample)
JP2015535847A5 (enExample)
JP2010529994A5 (enExample)
JP2009543795A5 (enExample)
JP2013533253A5 (enExample)
JP2013514980A5 (enExample)
JP2019516739A5 (enExample)